Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
Thomas B. Karasic(Hospital of the University of Pennsylvania), Peter J. O’Dwyer(University of Pennsylvania), Timothy J. Brown(Desert Research Institute), Tara C. Mitchell(Hospital of the University of Pennsylvania), Lisa Dicicco(University of Pennsylvania), Mark H. O’Hara(University of Pennsylvania), Charles Schneider(University of Pennsylvania), Ursina Teitelbaum(University of Pennsylvania), Luis Garcia-Marcano(University of Pennsylvania), Kim A. Reiss(University of Pennsylvania), Ryan Massa(University of Pennsylvania), Ravi K. Amaravadi(University of Pennsylvania)
Cited by 33
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Autophagy in major human diseases
|The EMBO Journal|2021|1.6k
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
|Journal of Clinical Investigation|2007|1.1k
Recent insights into the function of autophagy in cancer
|Genes & Development|2016|817